Print
Coronavirus

COVID Vaccine Made With Plants? It's The Subject Of Clinical Trial In Wilmington

By Cece Nunn, posted Apr 12, 2021
Trial Management Associates, a Wilmington clinical research firm, and Bart Williams and Will Jones of Wrightsville Family Practice are conducting a trial of a new COVID-19 vaccine using plant-based technology and plant cells, according to an announcement Monday.

Williams, the physician overseeing the trial, said in the news release, “The health and safety of our community continues to be the basis for our research. Finding safe and effective COVID-19 vaccines and having a community comfort level to actually receive the vaccine will be the main way we navigate out of this global pandemic.

"Some patients in our community are hesitant to receive the current COVID-19 vaccines approved by the FDA. We worked hard to secure this trial because the plant-based technology offers an alternative, and everyone who participates in the trial will ultimately receive the vaccine.”

Phil Dattilo, president of TMA, said his firm's mission is to bring as many therapies to the Wilmington community as possible. He could not say which company his firm is working with on the trial.

Dattilo said creating vaccines using plants isn't new.

"Plant-based vaccines have been around for quite some time for various uses, such as influenza A and influenza B vaccines," he said.

Explaining how the vaccine works, TMA’s pharmacist Evan Lucas said in the release, “The vaccine for this study is plant-based, meaning that it is produced inside of plants and plant cells instead of animal or human cells as many vaccines are.

"The plants produce virus-like particles, which look very similar to coronavirus but do not make you sick. These particles trigger the immune system to respond and produce antibodies, helping patients develop immunity against COVID-19.”

TMA is seeking up to 330 volunteers ages 18 and older, who have not already received a COVID vaccination, to participate in the study. Potential patients may have received other types of vaccines if they have done so 14 days prior to starting the study and may receive other vaccines 28 days after receiving the study vaccine.

The trial requires five in-office visits, and all patients will be compensated for their time and travel. Those who want to participate in Wilmington or the surrounding communities can contact TMA at [email protected] or call 247-4580.
Ico insights

INSIGHTS

SPONSORS' CONTENT
Georgiarowe

Salling and Tate Dentistry Launches Annual "Gunner’s Runners" Shoe Collection Event, Aiming to Surpass Last Year's Success

Georgia Rowe - Wide Open Tech
Headshots march websized 2

Is Your Commercial Roof Ready for April Showers?

David Grandey - Highland Roofing Company
Unknown 7112393341

Why Feasibility is Paramount to Success

Holly Segur - Lead Intuitively – Corporate Coaching

Trending News

Conservation Group Signs $8M Deal To Buy The Point On Topsail Island

Audrey Elsberry - Mar 26, 2024

Rezoning Could Bring 123 Townhomes To Growing Leland Corridor

Emma Dill - Mar 25, 2024

N.C. Ports Officials React To Baltimore Bridge Collapse

Audrey Elsberry - Mar 26, 2024

Engineering Firm Hires Four Employees

Staff Reports - Mar 26, 2024

National Organization Bestows Top Award On Cape Fear Professional Women In Building

Staff Reports - Mar 26, 2024

In The Current Issue

Topsail-area Realtors Share Updates

Pender County Realtors recently shared updates about the coastal market at an event hosted by the Wilmington-Cape Fear Home Builders Associa...


Hacking Cyberdefense Shortage

A shortage of cybersecurity professionals influenced professor Ulku Clark and her team to slowly evolve UNCW’s offerings to now include eigh...


Q&A: Andrews Reflects On Leadership

Pender County Manager David Andrews is slated to retire this summer after 33 years in local government....

Book On Business

The 2024 WilmingtonBiz: Book on Business is an annual publication showcasing the Wilmington region as a center of business.

Order Your Copy Today!


Galleries

Videos

2023 Power Breakfast: Major Developments